Tranquis Therapeutics
PrivateLast Round
Series A
Jul 9, 2020
Total Funding Raised
$30M
Company Overview
Tranquis Therapeutics operates in Healthcare & Life Sciences and is based in Palo Alto, California. Its latest recorded funding round was a Series A round in July 2020.
Tranquis Therapeutics is a biopharmaceutical company that develops small molecule drugs designed to reprogram dysfunctional myeloid immune cells to treat neurodegenerative and aging-related diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Tranquis Therapeutics Comparables
Compare Tranquis Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Monument Biosciences | 86% | |
| NeuroTherapia, Inc. | 86% | |
| Muna Therapeutics | 82% |
For institutional investors. Book with your work email.
Tranquis Therapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Tranquis Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Remiges Ventures | Series A |
| Correlation Ventures | Series A |
| SR One | Series A |
| Vivo Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 9, 2020
$30M round led by Remiges Ventures and SR One.
For institutional investors. Book with your work email.
Tranquis Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Tranquis Therapeutics's valuation, stock price, and market status.
Is Tranquis Therapeutics a public or private company?
Tranquis Therapeutics is a private company.
What is the current stock price of Tranquis Therapeutics?
Tranquis Therapeutics is a private company, so its shares have no public market price. Caplight tracks Tranquis Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Tranquis Therapeutics worth (valuation)?
Valuation information for Tranquis Therapeutics is not publicly available.
Can I buy Tranquis Therapeutics stock?
Tranquis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Tranquis Therapeutics's last funding round?
Tranquis Therapeutics's most recent funding round was Series A on July 9, 2020.
Who are the main investors in Tranquis Therapeutics?
Key investors in Tranquis Therapeutics include Remiges Ventures, SR One.
Will Tranquis Therapeutics IPO soon?
No public IPO plans have been announced for Tranquis Therapeutics.
How can I track Tranquis Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Tranquis Therapeutics's shares on secondary markets.